Kannan Rangaramanujam

Dr. Kannan Rangaramanujam is the Arnall Patz distinguished professor of ophthalmology and co-director of Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. He obtained his Ph.D. in Chemical Engineering from the California Institute of Technology. He plays a key role in Ashvattha from a scientific perspective, helping with identifying high-value therapeutic opportunities, product development, preclinical studies, and chemistry. He played a leading role in the development and validation of the dendrimer platform over the last 15 years, with >20 issued and 50 pending patents, licensed to Ashvattha. His research group at Hopkins Medicine works on translational nanomedicine centered on the unique hydroxyl dendrimer platform technology to develop treatments for inflammatory disorders. Targeted therapeutic approaches are being developed and validated in CNS, ocular and liver disorders, and oncology. He collaborates with more than 30 PI-level researchers at Hopkins on this platform, and has >100 peer-reviewed publications, with significant, sustained funding support from NIH. He has won several recognitions, including a fellowship of the American Institute of Medical and Biological Engineers (AIMBE) and NSF CAREER award.